Tag Archives: oncology

OXIS International, Inc. (OTCMKTS:OXIS) just announced that it has entered into a sponsored research agreement with the University of Minnesota, designed to help forward the development of one of its preclinical assets. This is a company we’ve...

Towards the end of last year, we took a look at a small biotech play called Q BioMed Inc (OTCMKTS:QBIO). The company had just logged some gains, and had drawn our attention on the back of this run. At that point, Q BioMed was going for around...

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) ran up towards the end of last week on basically no news, and is running again early session in the US on Monday. March to date, the company is up more than 75%. This company is gaining speculative...

Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) has been a real tough stock to hold over the last couple of years. It’s fallen prey to aggressive short sell type manipulation. It’s had clinical halt related development setbacks for...

HTG Molecular Diagnostics Inc (NASDAQ:HTGM) spiked at the end of last month, running up from $1.2 a share to $3.1 a share, on volume of close to 20 million shares changing hands. That’s a nearly 160% gain in a session. The company has...

Premier Biomedical Inc (OTCMKTS:BIEI) is a company we first looked at last summer. At the time, the company had just put out some information regarding what it calls its extracorporeal therapy platform, and we noted that this platform was young,...

ImmunoGen, Inc. (NASDAQ:IMGN) put out its latest earnings last week, and markets were pretty much flat on the news. That’s a correct response in our opinion – these numbers mean very little for a company at the stage in which Immunogen...

At the end of last month, Cannabis Science Inc (OTCMKTS:CBIS) got a big boost on the back of some news that the company had sold out on an initial test run of one of its lead products. A sold out test run is great news, of course, but in the...

Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) has been a real swing stock over the last few weeks. The company ran form less than a dollar a share at the beginning of February to close to $6.5 a piece on February 21. A pretty sharp correction...

Celsion Corporation (NASDAQ:CLSN) has been a tough stock to hold over the last few years. Following a high profile run up, and subsequent collapse, back in early 2013, the company has basically deteriorated in value almost painfully slowly,...

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter